RBC Capital cuts EyePoint stock price target on trial miss
RBC Capital cut EyePoint Inc.'s (NASDAQ:EYPT) price target to $1.00 from $5.00 after its LUCIA trial failed, sending shares down 85%. The company's market cap fell to $37.93M. EyePoint is considering options for wAMD and maintains a cash runway into Q4 2027. Multiple firms downgraded EYPT following the trial results.
How this was made
The 30-second read
Why it matters
The trial miss is a primary catalyst that materially affects valuation; the market has already reacted strongly.
Market read
EyePoint's stock is under severe pressure; the news is relevant for traders with exposure to biotech and ophthalmology sectors.
What to watch
Cash runway of $118 million provides runway to fund additional studies, which could mitigate downside if data improve.
Background
EyePoint reported a Phase 3 trial failure for its wet‑AMD drug Duravyu, prompting a sharp price drop and analyst downgrades.
Ticker impact
RBC Capital cut EyePoint's price target to $1 after the LUCIA trial missed its primary endpoint, sending the stock down 85%.
likely continued downside as investors price in the failed trial and lower target.
Clinical‑trial failure is a material catalyst for a biotech; multiple analyst downgrades reinforce the bearish outlook.
Market effects
Other wet‑AMD biotech peers may see heightened scrutiny and short‑interest.
US biotech sector could face slight pullback amid the negative news.
Limited; impact confined to EyePoint and closely related ophthalmology stocks.
Counterpoint
If the company can pivot to diabetic macular edema data, the stock may be undervalued after the sell‑off.
Key entities
- companyEyePoint Inc.
Biotech firm developing Duravyu for wet age‑related macular degeneration.
- analystRBC Capital
Reduced price target to $1 from $5.
